Synthrox is interesting with a USD $2.5B buyout at Phase 1 (albeit early Phase 1). Based on metrics I've captured buyouts are typically around 5x peak sales. This implies peak sales around USD $500M, although I did find a peer drug with peak sales estimated at USD $1B.
My current peak sales estimate for Bisantrene is around USD $44B.
USD $44B / USD $500M = 88 x
USD $44B / USD $1B = 44 x
So by my estimates Bisantrene has 44 x to 88 x the potential of the pipeline purchased by Sanofi from Synthorx.
RAC - Charts & Price Action, page-6511
-
- There are more pages in this discussion • 15,660 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.020(1.19%) |
Mkt cap ! $282.8M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.61 | $153.5K | 94.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 4080 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |